Predicting breast cancer therapeutic response
- PMID: 29736021
- DOI: 10.1038/s41591-018-0033-7
Predicting breast cancer therapeutic response
Comment on
-
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30. Nat Med. 2018. PMID: 29713086 Free PMC article. Clinical Trial.
Similar articles
-
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30. Lancet Oncol. 2014. PMID: 24794243 Clinical Trial.
-
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28. Lancet Oncol. 2018. PMID: 29501363 Clinical Trial.
-
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.Oncotarget. 2016 Sep 13;7(37):60647-60656. doi: 10.18632/oncotarget.10607. Oncotarget. 2016. PMID: 27447966 Free PMC article. Clinical Trial.
-
Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer.Rev Recent Clin Trials. 2015;10(2):101-10. doi: 10.2174/1574887110666150624101343. Rev Recent Clin Trials. 2015. PMID: 26104428 Review.
-
Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?Clin Adv Hematol Oncol. 2014 Oct;12(10):654-8. Clin Adv Hematol Oncol. 2014. PMID: 25658890 Review.
Cited by
-
In the literature: June 2018.ESMO Open. 2018 Jun 20;3(4):e000401. doi: 10.1136/esmoopen-2018-000401. eCollection 2018. ESMO Open. 2018. PMID: 29942668 Free PMC article. No abstract available.
-
A TIMM17A Regulatory Network Contributing to Breast Cancer.Front Genet. 2021 Aug 5;12:658154. doi: 10.3389/fgene.2021.658154. eCollection 2021. Front Genet. 2021. PMID: 34421983 Free PMC article.
-
Techniques to produce and evaluate realistic multivariate synthetic data.Sci Rep. 2023 Jul 28;13(1):12266. doi: 10.1038/s41598-023-38832-0. Sci Rep. 2023. PMID: 37507387 Free PMC article.
References
-
- Siegel, R. L., Miller, K. D. & Jemal, A. CA Cancer J. Clin. 68, 7–30 (2018). - DOI
-
- Perou, C. M. Oncologist 15 Suppl. 5, 39–48 (2010). - DOI
-
- Miki, Y. et al. Science 266, 66–71 (1994). - DOI
-
- Wooster, R. et al. Nature 378, 789–792 (1995). - DOI
-
- Wong-Brown, M. W. et al. Breast Cancer Res. Treat. 150, 71–80 (2015). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical